Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)

Les Laboratoires des Médicaments Stériles219 enrolled

Overview

This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: * Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after the last maintenance dose (75 mg). * Secondary Outcome Measures: Time to first occurrence of major cardio-vascular events (MACE). * Safety Criteria: severe bleeding (GUSTO scale).

after randomization of patients in both groups (Plavix or Pidogrel), the measure of platelet activity by the VerifyNow assay, 4 to 12 hours after the loading dose of 600mg or after the last dose of clopidogrel for patients on maintenance dose. The VerifyNow assay will determine: - The PRU:-P2Y12 Reaction Units- -% Of platelet inhibition It will be considered low responder or clopidogrel resistant patient with PRU\> 235 or %inhibition \<15%. Monitoring of patients included in the study will take place over a period of 12 months, MACE will be notified and dated. MACE criteria are: angina, myocardial infarction, coronary angioplasty, coronary artery bypass graft, and stroke. Each hemorrhagic event will be notified and classified according to the GUSTO scale.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

219

Conditions

Coronary Disease

Interventions

PidogrelDRUG

Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.

PlavixDRUG

Plavix(R) 75 mg/day for period ranging from 1 to 6 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, * Old (e) over 20 years * Patients hospitalized for acute coronary syndrome (Whatever the T and troponin) * Patients with proven coronary candidates for treatment with clopidogrel (who received a loading dose of 600mg over 2 hours and treated with 75mg / d of clopidogrel for longer than 7 days) Exclusion Criteria: * Patients unwilling. * Patient participating in another study. * Patients with cardiogenic shock * Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability * Patients scheduled for surgery in less than 6 months. * Patients candidates for coronary angioplasty * Patients who underwent TAC + / - bare stent fewer than 30 days. * Patients who underwent stenting with ATC active there is less than 12 months. * ischemic stroke older than 6 weeks. * History of hemorrhagic stroke (any time) * Patients on warfarin or candidates * Patients with a different anti ADP (ticlopidine, prasugrel) * Patients with indication for clopidogrel-cons (side effects, bleeding ...) * Thrombocytopenia \<100000/mm3 * anemia (Ht \<30%) * Thrombocythaemia (Ht\> 52%) * Patients seeking treatment for an elective forms of Clopidogrel. * Pregnancy

Locations (1)

cardiology department, hospital La RABTA

Tunis, Tunis BAB Souika, Tunisia

Outcomes

Primary Outcomes

- study the respective effects of Pidogrel ® and Plavix ® on platelet aggregation through the test VerifyNow ® - Time to first occurrence of post-randomization major adverse cardiac events (MACE)

Time frame: 06 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.